Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenserine Axonyx.

Urmila Thatte1

  • 1Department of Clinical Pharmacology, TN Medical College, Mumbai 400 008, India. mthatte@bom5.vsnl.net.in

Current Opinion in Investigational Drugs (London, England : 2000)
|July 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective study to assess the role of paraoxonase 1 genotype and phenotype on the lipid-lowering and antioxidant activity of statins.

Indian journal of pharmacology·2023
Same author

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.

The European respiratory journal·2022
Same author

Association of <i>PON1</i> gene polymorphisms and enzymatic activity with risk of coronary artery disease.

Future cardiology·2020
Same author

Single-dose and Steady-state Pharmacokinetics of Vancomycin in Critically Ill Patients Admitted to Medical Intensive Care Unit of India.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2020
Same author

An Expert Review and Recommendations on the Rational Use of Proton Pump Inhibitors: Indian Perspective.

The Journal of the Association of Physicians of India·2019
Same author

Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach.

Indian journal of pharmacology·2019
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Phenserine, an Alzheimer's disease drug candidate, failed to meet primary endpoints in Phase III trials. Patient recruitment was suspended, but reformulation plans are underway.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Phenserine is an acetylcholinesterase inhibitor developed for Alzheimer's disease.
  • It is the (-)-enantiomer of a physostigmine derivative.
  • Axonyx licensed the drug candidate from the National Institutes of Health/National Institute on Aging.

Purpose of the Study:

  • To evaluate the efficacy of phenserine in Phase III clinical trials for Alzheimer's disease.
  • To assess the drug's potential as a therapeutic agent for cognitive decline associated with Alzheimer's.

Main Methods:

  • Phase III clinical trials were conducted to assess phenserine's efficacy.
  • Patient recruitment was a key component of the trial methodology.

Main Results:

Related Experiment Videos

  • The drug failed to meet the primary endpoints of the initial Phase III trial.
  • Patient recruitment was suspended following the trial results.

Conclusions:

  • Phenserine did not demonstrate sufficient efficacy to meet the primary endpoints in its initial Phase III trial.
  • Despite trial setbacks, the developing company planned to reformulate the drug for potential future development.